Development and evaluation of chitosan microspheres for tetanus, diphtheria and divalent vaccines: A comparative study of subcutaneous and intranasal administration in mice

Pharmaceutical Development and Technology

Volumn 18, Issue 5, 2013, Pages 1175-1185

  Hashem, Fahima M ^a   Fahmy, Sahar A ^a   El Sayed, Aly M ^b   Al Sawahli, Majid M ^a  

^a Helwan   (Egypt)

^b Holding Company for Biological Products and Vaccines   (Egypt)

Author keywords

Controlled release; Immunogenicity in mice; Microparticles; Single shot vaccine; Vaccine delivery

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIBODY; ANTIGEN; BACTERIAL VACCINE; CHITOSAN; DIPHTHERIA VACCINE; DIVALENT VACCINE; MICROSPHERE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; ENCAPSULATION; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MORPHOLOGY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; VIRUS RELEASE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES; ANTIGENS; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DIPHTHERIA; DIPHTHERIA TOXOID; DIPHTHERIA-TETANUS VACCINE; DRUG DELIVERY SYSTEMS; MALE; MICE; MICROSPHERES; PARTICLE SIZE; TETANUS; TETANUS TOXOID;

EID: 84887465337     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2011.618949     Document Type: Article

References (45)

1. Vila A, Sánchez A, Tobío M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release 2002;78:15-24.
2. Almeida AJ, Alpar HO, Brown MR. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(l-lactic acid) microspheres in rats, rabbits and guinea-pigs. J Pharm Pharmacol 1993;45:198-203.
3. Aguado MT. Future approaches to vaccine development: Single-dose vaccines using controlled-release delivery systems. Vaccine 1993;11:596-597.
4. Mohanan D, Slütter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y et al. Administration routes afect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. J Control Release 2010;147:342-349.
5. Bowey K, Neufeld RJ. Systemic and mucosal delivery of drugs within polymeric microparticles produced by spray drying. BioDrugs 2010;24:359-377.
6. Shi L, Caulfeld MJ, Chern RT, Wilson RA, Sanyal G, Volkin DB. Pharmaceutical and immunological evaluation of a single shot hepatitis B vaccine formulated with PLGA microspheres. J Pharm Sci 2002;91:1019-1035.
7. Singh M, Chakrapani A, O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007;6:797-808.
8. Jaganathan KS, Rao YU, Singh P, Prabakaran D, Gupta S, Jain A et al. Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(d, l-lactic-co-glycolic acid) versus chitosan microspheres. Int J Pharm 2005;294:23-32.
9. Singh M, Li XM, Wang H, McGee JP, Zamb T, Kof W et al. Controlled release microparticles as a single dose diphtheria toxoid vaccine: Immunogenicity in small animal models. Vaccine 1998;16:346-352.
10. Dani BA, DeLuca PP. Preparation, characterization, and in vivo evaluation of salmon calcitonin microspheres. AAPS PharmSciTech 2001;2:22.
11. Kofuji K, Akamine H, Oshirabe H, Maeda Y, Murata Y, Kawashima S. Retention and release behavior of insulin in chitosan gel beads. J Biomater Sci Polym Ed 2003;14:1243-1253.
12. Kofuji K, Murata Y, Kawashima S. Sustained insulin release with biodegradation of chitosan gel beads prepared by copper ions. Int J Pharm 2005;303:95-103.
13. Ge YB, Chen DW, Xie LP, Zhang RQ. Optimized preparation of daidzein-loaded chitosan microspheres and in vivo evaluation after intramuscular injection in rats. Int J Pharm 2007;338:142-151.
14. Alonso MJ, Cohen S, Park TG, Gupta RK, Siber GR, Langer R. Determinants of release rate of tetanus vaccine from polyester microspheres. Pharm Res 1993;10:945-953.
15. Schwendeman SP, Costantino HR, Gupta RK, Tobio M, Chang AC, Alonso MJ et al. Strategies for stabilising tetanus toxoid towards the development of a single-dose tetanus vaccine. Dev Biol Stand 1996;87:293-306.
16. Zhu G, Mallery SR, Schwendeman SP. Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide). Nat Biotechnol 2000;18:52-57.
17. Johansen P, Men Y, Audran R, Corradin G, Merkle HP, Gander B. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm Res 1998;15:1103-1110.
18. Illum L. (1998). Bioadhesive formulations for nasal peptide delivery. In: Mathiowitz E, Lehr CM, Chickering D (eds). Drug delivery-issues in fundamentals-Novel approaches and development. New York: Marcel Dekker, pp. 507-539.
19. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 2001;52:139-144.
20. Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994;11:1186-1189.
21. Soane RJ, Hinchclife M, Davis SS, Illum L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 2001;217:183-191.
22. Illum L, Watts P, Fisher AN, Jabbal-Gill I, Davis SS. Novel chitosan based delivery systems for nasal administration of a LHRH-analogue. STP Pharma 2000;10:89-94.
23. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 1999;178:55-65.
24. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994;11:1358-1361.
25. Hames BD, Rickwood D. (1991). Gel Electrophoresis of Proteins: A Practical Approach. New York, USA: Oxford University Press.
26. Lee JH, Park TG, Lee YB, Shin SC, Choi HK. Effect of adding non-volatile oil as a core material for the foating microspheres prepared by emulsion solvent difusion method. J Microencapsul 2001;18:65-75.
27. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
28. el-Karamany RM. Production in Vero cells of an inactivated rabies vaccine from strain FRV/K for animal and human use. Acta Virol 1987;31:321-328.
29. Gohel MC, Sheth MN, Jani GK, Patel H. Design of chitosan microspheres containing diclofenac sodium. Ind J Pharm Sci 1994;56:210-214.
30. Manivannan R, Dhanaraj SA, Rao YU, Balasubramaniam A, Gowrishankar NL, Jawahar N et al. In vivo evaluation of single dose tetanus toxoid vaccine formulation with chitosan microspheres. Indian J Pharm Sci 2008;70:11-15.
31. Baxendalea AJ, Hoofa PV, Durrantb LG, Spendloveb I, Howdlea SM, Woods HM et al. Single shot tetanus vaccine manufactured by a supercritical fuid encapsulation technology. Int J Pharm 2011;413:147-154.
32. Gupta KC, Jabrail FH. Glutaraldehyde and glyoxal cross-linked chitosan microspheres for controlled delivery of centchroman. Carbohydr Res 2006;341:744-756.
33. Chang AC, Gupta RK. Stabilization of tetanus toxoid in poly(dl-lactic-co-glycolic acid) microspheres for the controlled release of antigen. J Pharm Sci 1996;85:129-132.
34. Dineshkumar B, Dhanaraj SA, Santhi K Vijayan P, Chandrasekhar R. Single dose vaccine delivery system of tetanus toxoid formulation based on chitosan microspheres. Int J Adv Pharm Sci 2010;1:42-49.
35. Jameela SR, Kumary T V, Lal AV, Jayakrishnan A. Progesterone-loaded chitosan microspheres: A long acting biodegradable controlled delivery system. J Control Release 1998;52:17-24.
36. Prabaharan M, Mano JF. Chitosan-based particles as controlled drug delivery systems. Drug Deliv 2005;12:41-57.
37. Ponchel G, Touchard F, Duchene D, Pepas NA. Bioadhesive analysis of controlled-release systems, I: Fracture and interpenetration analysis in poly (acrylic acid)-containing systems. J Control Release 1987;5:129-141.
38. Amin M, Jaafari MR, Tafaghodi M. Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. Colloids Surf B Biointerfaces 2009;74:225-229.
39. Department of Health and Human Services, Food and Drug Administration. Biological products; bacterial vaccines and toxoids; implementation of efcacy review; proposed rule. Federal Register 1985;50:51002-51117.
40. Abrahamian FM, Pollack CV Jr, LoVecchio F, Nanda R, Carlson RW. Fatal tetanus in a drug abuser with "protective" antitetanus antibodies. J Emerg Med 2000;18:189-193.
41. Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev 2009;61:140-157.
42. Chaudhari M, Jadhav KR, Kadam VJ. An over view: Microspheres as a nasal drug delivery system. Int J Pharm Sci Rev Res 2010;5:8-17.
43. Niclas R, Ingvar S. Mucosal vaccination against diphtheria using starch microparticles as adjuvant for cross-reacting material (CRM197) of diphtheria toxin. Vaccine 2005;23:2775-2783.
44. Osth K, Strindelius L, Larhed A, Ahlander A, Roomans GM, Sjöholm I et al. Uptake of ovalbumin-conjugated starch microparticles by pig respiratory nasal mucosa in vitro. J Drug Target 2003;11:75-82.
45. Singh M, Li XM, Wang H, McGee JP, Zamb T, Kof W et al. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect Immun 1997;65:1716-1721.